Bahrain vs Mus: HIV-positive TB patients on ART (antiretroviral therapy)
Bahrain
100.0%
in 2023
Mus
100.0%
in 2024
Bahrain rank
1st
Mus rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Bahrain
- Mus
How they compare
Bahrain currently reports 100.0% against 100.0% in Mus, a difference of 0.0%.
The two have swapped places 4 times across 12 shared years of data; in 2008 it was Mus ahead.
Bahrain ranks 1st and Mus ranks 1st of 144 countries.
Mus has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Bahrain | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 13.0% | 60.5% | 47.5% | Mus |
| 2010s | 66.2% | 81.2% | 15.0% | Mus |
| 2020s | 57.5% | 100.0% | 42.5% | Mus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Bahrain or Mus?
- Bahrain, at 100.0% against 100.0% in Mus as of 2023.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Bahrain and Mus?
- 0.0%, with Bahrain ahead.
- How many years of comparable data are there for Bahrain and Mus?
- 12 years are reported by both, from 2008 to 2023.
- How do Bahrain and Mus rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Bahrain ranks 1st and Mus ranks 1st of 144 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.